Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20793005 | 0.98 | CNR2 (0.33) | CNR2ARMEN1PABPC1KMT2A | |
| SCHEMBL24656620 | 0.98 | CNR2 (0.33) | CNR2ARMEN1PABPC1KMT2A | |
| SCHEMBL24656031 | 0.98 | CNR2 (0.33) | CNR2ARMEN1PABPC1KMT2A | |
| SCHEMBL21783853 | 0.95 | CNR2 (0.32) | CNR2MEN1PABPC1KMT2ASIRT6 | |
| SCHEMBL18516775 | 0.93 | CNR2 (0.34) | CNR2MEN1PABPC1KMT2ASIRT6 | |
| SCHEMBL18522956 | 0.86 | CNR2 (0.39) | CNR2MEN1PABPC1KMT2ASIRT6 | |
| SCHEMBL23502537 | 0.85 | CNR2 (0.34) | CNR2KDM4ETSHRCNR1 | |
| SCHEMBL23502540 | 0.85 | CNR2 (0.34) | CNR2KDM4ETSHRCNR1 | |
| SCHEMBL22858660 | 0.80 | GABRP (0.35) | CNR2MEN1KMT2AKDM4EMAPT | |
| SCHEMBL19646395 | 0.80 | GABRP (0.35) | CNR2MEN1KMT2AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344016-B2 | Bromotriazole intermediates | AMGEN INC. (US) | 2019-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344016-B2 | Bromotriazole intermediates | APH1A, BRDT, APH1B | CNR2 655/4885AR 474/4885MEN1 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.